Skip to main content
. 2024 Apr 23;24:141. doi: 10.1186/s12876-024-03224-9

Table 2.

Comparison of patient characteristics, therapy, and outcome within the four calcium-trajectory phenotypes

Very low TSC, slow resolvers (n = 65) Moderately low TSC (n = 559) Stable normal-calcium (n = 3875) Fluctuating high TSC (n = 19) P
Age (years) 54.3 ± 15.0 57.6 ± 17.4 56.3 ± 17.0 55.0 ± 13.4 0.232
Male, n (%) 36 (55.4) 298 (53.3) 2012 (51.9) 13 (68.4) 0.447
Race, n (%) < 0.001
 White 50 (76.9) 343 (61.4) 2672 (69.0) 13 (68.4)
 Black 2 (3.1) 58 (10.4) 533 (13.8) 1 (5.3)
 Other 13 (20.0) 158 (28.3) 670 (17.3) 5 (26.3)
Comorbidities, n (%)
 Congestive heart failure 9 (13.8) 88 (15.7) 411 (10.6) 1 (5.3) 0.003
 Chronic pulmonary disease 13 (20.0) 91 (16.3) 632 (16.3) 2 (10.5) 0.774
 Chronic renal failure 11 (16.9) 69 (12.3) 454 (11.7) 5 (26.3) 0.136
 Metastatic cancer 3 (4.6) 8 (1.4) 113 (2.9) 2 (10.5) 0.029
 Liver disease 23 (35.4) 173 (30.9) 692 (17.9) 4 (21.1) < 0.001
Disease severity and laboratory indexes
 SOFA score (median [IQR]) 8.0 [4.0, 13.0] 6.0 [3.0, 10.0] 4.0 [2.0, 7.0] 5.0 [3.0, 10.0] < 0.001
 Minimum albumin, mg/dL 2.5 ± 0.6 2.8 ± 0.6 3.4 ± 0.7 2.9 ± 0.4 < 0.001
 Minimum bicarbonate, mmol/L 15.8 ± 4.8 18.4 ± 5.3 24.0 ± 4.2 23.1 ± 6.7 < 0.001
 Maximum bilirubin, mg/dL 2.0 ± 2.1 2.6 ± 4.2 1.9 ± 3.5 2.4 ± 2.5 0.004
 Maximum creatinine, mg/dL 2.6 ± 2.2 2.0 ± 2.4 1.2 ± 1.3 2.2 ± 1.9 < 0.001
 Maximum BUN, mg/dL 35.7 ± 27.4 30.7 ± 26.8 18.6 ± 17.9 42.3 ± 26.2 < 0.001
 Maximum glucose, mg/dL 225.2 ± 125.8 185.9 ± 118.1 132.2 ± 83.1 162.4 ± 88.7 < 0.001
 Maximum white blood cell count (10^9/L) 14.4 ± 8.5 14.8 ± 8.5 10.6 ± 7.4 12.0 ± 5.3 < 0.001
 Maximum amylase, IU/L 383.0 [118.0, 702.0] 212.0 [77.0, 580.0] 144.0 [64.0, 484.0] 54.0 [43.0, 185.5] 0.001
 Maximum lipase, IU/L 617.0 [230.8, 1225.2] 292.0 [78.0, 920.0] 156.0 [49.0, 714.5] 96.0 [37.0, 209.0] < 0.001
Clinical outcomes
 In-hospital death 14 (21.5) 96 (17.2) 146 (3.8) 3 (15.8) < 0.001
 ICU admission, n (%) 58 (89.2) 470 (84.1) 1110 (28.6) 16 (84.2) < 0.001
 Hospital length of stay, days, (median [IQR]) 20.6 [11.8, 32.9] 10.0 [4.9, 18.1] 4.9 [2.8, 9.0] 16.6 [8.3, 23.7] < 0.001
 Antibiotic use, n (%) 55 (84.6) 364 (65.1) 1719 (44.4) 13 (68.4) < 0.001
 Intubation, n (%) 38 (58.5) 234 (41.9) 346 (8.9) 7 (36.8) < 0.001
 RRT, n (%) 20 (30.8) 49 (8.8) 71 (1.8) 3 (15.8) < 0.001

SOFA, Sequential Organ Failure Assessment; BUN, Blood urea nitrogen; RRT, renal replace treatment